Patents by Inventor Philipp Lustenberger

Philipp Lustenberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORM OF LNP023
    Publication number: 20230265067
    Abstract: Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.
    Type: Application
    Filed: February 14, 2023
    Publication date: August 24, 2023
    Inventors: Zichen JIA, Philipp LUSTENBERGER, Marie MEYER, Massimo MORATTO
  • Crystalline form of LNP023
    Patent number: 11603363
    Abstract: Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: March 14, 2023
    Assignee: Novartis AG
    Inventors: Zichen Jia, Philipp Lustenberger, Marie Meyer, Massimo Moratto
  • CRYSTALLINE FORM OF LNP023
    Publication number: 20210371394
    Abstract: Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.
    Type: Application
    Filed: May 17, 2021
    Publication date: December 2, 2021
    Inventors: Zichen JIA, Philipp LUSTENBERGER, Marie MEYER, Massimo MORATTO
  • Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid
    Patent number: 10723735
    Abstract: This invention relates to novel processes for synthesizing [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid and to intermediates that are used in such processes.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: July 28, 2020
    Inventors: Fabrice Gallou, Philipp Lustenberger, Christian Mathes, Qiangbiao Pan, Benli Zou
  • PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID
    Publication number: 20200031824
    Abstract: This invention relates to novel processes for synthesizing [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid and to intermediates that are used in such processes.
    Type: Application
    Filed: March 29, 2018
    Publication date: January 30, 2020
    Inventors: Fabrice Gallou, Philipp Lustenberger, Christian Mathes, Qiangbiao Pan, Benli Zou
  • Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo [2,3-B]pyridin-3-yl-acetic acid
    Patent number: 10508110
    Abstract: This invention relates to novel processes for synthesizing [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid and to intermediates that are used in such processes.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: December 17, 2019
    Assignee: NOVARTIS AG
    Inventors: Philipp Lustenberger, Christian Mathes, Zhongbo Fei, Bernard Riss, Thierry Schlama
  • Benzothiazolone compound
    Patent number: 10251868
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: April 9, 2019
    Assignee: NOVARTIS AG
    Inventors: Jun Cao, Bernhard Erb, Robin Alec Fairhurst, Arnaud Grandeury, Shinji Hatakeyama, Magdalena Koziczak-Holbro, Xinzhong Lai, Philipp Lustenberger, Bernd Ulrich Riebesehl, Nicola Tufilli, Thomas Ullrich, Xiang Wu, Jianguang Zhou
  • PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID
    Publication number: 20180273530
    Abstract: This invention relates to novel processes for synthesizing [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid and to intermediates that are used in such processes.
    Type: Application
    Filed: September 27, 2016
    Publication date: September 27, 2018
    Inventors: Philipp Lustenberger, Christian Mathes, Zhongbo Fei, Bernard Riss, Thierry Schlama
  • BENZOTHIAZOLONE COMPOUND
    Publication number: 20180140582
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Application
    Filed: January 22, 2018
    Publication date: May 24, 2018
    Applicant: NOVARTIS AG
    Inventors: Jun CAO, Bernhard ERB, Robin Alec FAIRHURST, Arnaud GRANDEURY, Shinji HATAKEYAMA, Magdalena KOZICZAK-HOLBRO, Xinzhong LAI, Philipp LUSTENBERGER, Bernd Ulrich RIEBESEHL, Nicola TUFILLI, Thomas ULLRICH, Xiang WU, Jianguang ZHOU
  • Benzothiazolone compound
    Patent number: 9913828
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: March 13, 2018
    Assignee: NOVARTIS AG
    Inventors: Jun Cao, Bernhard Erb, Robin Alec Fairhurst, Arnaud Grandeury, Shinji Hatakeyama, Magdalena Koziczak-Holbro, Xinzhong Lai, Philipp Lustenberger, Bernd Ulrich Riebesehl, Nicola Tufilli, Thomas Ullrich, Xiang Wu, Jianguang Zhou
  • BENZOTHIAZOLONE COMPOUND
    Publication number: 20160279107
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Application
    Filed: June 10, 2016
    Publication date: September 29, 2016
    Applicant: NOVARTIS AG
    Inventors: Jun CAO, Bernhard ERB, Robin Alec FAIRHURST, Arnaud GRANDEURY, Shinji HATAKEYAMA, Magdalena KOZICZAK-HOLBRO, Xinzhong LAI, Philipp LUSTENBERGER, Bernd Ulrich RIEBESEHL, Nicola TUFILLI, Thomas ULLRICH, Xiang Wu, Jianguang ZHOU
  • BENZOTHIAZOLONE COMPOUND
    Publication number: 20160075670
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Application
    Filed: November 20, 2015
    Publication date: March 17, 2016
    Applicant: NOVARTIS AG
    Inventors: Jun CAO, Bernhard ERB, Robin Alec FAIRHURST, Arnaud GRANDEURY, Shinji HATAKEYAMA, Magdalena KOZICZAK-HOLBRO, Philipp LUSTENBERGER, Bernd RIEBESEHL, Nicola TUFILLI, Thomas ULLRICH, Xiang WU, Jianguang ZHOU
  • BENZOTHIAZOLONE COMPOUND
    Publication number: 20150336914
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Application
    Filed: August 3, 2015
    Publication date: November 26, 2015
    Applicant: NOVARTIS AG
    Inventors: Jun CAO, Bernhard ERB, Robin Alec FAIRHURST, Arnaud GRANDEURY, Shinji HATAKEYAMA, Magdalena KOZICZAK-HOLBRO, Philipp LUSTENBERGER, Bernd RIEBESEHL, Nicola TUFILLI, Thomas ULLRICH, Xiang WU, Jianguang ZHOU
  • BENZOTHIAZOLONE COMPOUND
    Publication number: 20150094346
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Application
    Filed: December 10, 2014
    Publication date: April 2, 2015
    Applicant: NOVARTIS AG
    Inventors: Jun CAO, Bernhard ERB, Robin Alec FAIRHURST, Arnaud GRANDEURY, Shinji HATAKEYAMA, Magdalena KOZICZAK-HOLBRO, Philipp LUSTENBERGER, Bernd RIEBESEHL, Nicola TUFILLI, Thomas ULLRICH, Xiang WU, Jianguang ZHOU
  • Benzothiazolone compound
    Patent number: 8933108
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: January 13, 2015
    Assignee: Novartis AG
    Inventors: Jun Cao, Bernhard Erb, Robin Alec Fairhurst, Arnaud Grandeury, Shinji Hatakeyama, Magdalena Koziczak-Holbro, Xinzhong Lai, Philipp Lustenberger, Bernd Riebesehl, Nicola Tufilli, Thomas Ullrich, Xiang Wu, Jianguang Zhou
  • Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
    Patent number: 8618132
    Abstract: The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: December 31, 2013
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Thorsten Lehmann-Lintz, Klaus Rudolf, Philipp Lustenberger, Kristen Arndt, Ralf R. H. Lotz, Martin Lenter
  • BENZOTHIAZOLONE COMPOUND
    Publication number: 20130245080
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Application
    Filed: September 5, 2012
    Publication date: September 19, 2013
    Applicant: NOVARTIS AG
    Inventors: Jun CAO, Bernhard ERB, Robin Alec FAIRHURST, Arnaud GRANDEURY, Shinji HATAKEYAMA, Magdalena KOZICZAK-HOLBRO, Xinzhong LAI, Philipp LUSTENBERGER, Bernd RIEBESEHL, Nicola TUFILLI, Thomas ULLRICH, Xiang WU, Jianguang ZHOU
  • Processes for the preparation of 4-oxo-octahydro-indole-1-carbocyclic acid methyl ester and derivatives thereof
    Patent number: 8084487
    Abstract: The present invention relates to a process for the production of carbamic acid (2-chloroethyl)(3-oxocyclohexyl)-alkyl ester enantiomers and of 1-carbalkoxy-4-ketoperhydroindole enantiomers.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: December 27, 2011
    Assignee: Novartis AG
    Inventors: Ernst Kuesters, Murat Acemoglu, Philipp Lustenberger, Gottfried Sedelmeier, Beat Schmitz, Gerhard Penn
  • Medicaments for the treatment of chronic obstructive pulmonary disease
    Patent number: 8044046
    Abstract: A pharmaceutical composition comprising a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R2 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R3 is hydrogen, C1-C4-alkyl, OH, halogen, —O—C1-C4-alkyl, —O—C1-C4-alkylene-COOH, or —O—C1-C4-alkylene-CO—O—C1-C4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: October 25, 2011
    Assignee: Boehringer Ingelheim Pharma GmbH & Co KG
    Inventors: Ingo Konetzki, Kurt Schromm, Hermann Schollenberger, Sabine Pestel, Andreas Schnapp, Thierry Bouyssou, Frank Buettner, Claudia Heine, Philipp Lustenberger, Christoph Hoenke, Klaus Rudolf
  • Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
    Patent number: 8034809
    Abstract: Enantiomerically pure compounds of general formula 1 wherein the groups R1, R2, R3, R4, and X? may have the meanings given in the claims and in the specification, processes for preparing them and the use thereof as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: October 11, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Philipp Lustenberger, Ingo Konetzki, Peter Sieger